Re: Cost-effectiveness of pertussis booster vaccination in the Netherlands

Vaccine

Volumn 30, Issue 50, 2012, Pages 7141-

  O'Mahony, James F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; LETTER; NETHERLANDS; PERTUSSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84869866472     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.042     Document Type: Letter

References (5)

1. Rozenbaum M.H., De Cao E., Postma MJ Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine 2012, 30:7327-7331.
2. Lipscomb J., Weinstein M.C., Torrence G.W. Time preference. Cost-effectiveness in health and medicine 1996, 214-246. Oxford University Press, Oxford. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
3. CVZ Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie 2006, College voor Zorgverzekeringen, Diemen, [in Dutch].
4. Gravelle H., Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001, 10(7):587-599.
5. O'Mahony J.F., de Kok I.M.C.M., van Rosmalen J., Habbema J.D.F., Brouwer W., van Ballegooijen M. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health 2011, 14(4):438-442.